Amrutanjan Health Care Ltd
Amrutanjan Health Care Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹110Cr
- +11.1% YoY
- Net profit
- ₹12Cr
- +71.4% YoY
- Margin
- 12%
- +5 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Amrutanjan Health Care Ltd Q2 FY25 key numbers
- Revenue
- Q2 FY25 Net Sales: Rs. 109.92 Cr, up 10.68% YoY.
As stated in Amrutanjan Health Care Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Amrutanjan Health Care Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY25 Net Sales: Rs. 109.92 Cr, up 10.68% YoY.
From Amrutanjan Health Care Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Net Sales: Rs. 109.92 Cr, up 10.68% YoY.
- Q2 FY25 OTC Sales: Rs. 106.26 Cr, up 12.95% YoY.
- Q2 FY25 Comfy Sales: Rs. 33.00 Cr, up 27.96% YoY.
- Q2 FY25 Beverages Sales: Rs. 3.39 Cr, down from Rs. 4.88 Cr YoY.
- Q2 FY25 Electro Plus Sales: Rs. 3.16 Cr, slightly down from Rs. 3.25 Cr YoY.
- H1 FY25 Net Sales: Rs. 193.65 Cr, up 9.30% YoY.
- H1 FY25 OTC Sales: Rs. 178.89 Cr, up 11.65% YoY.
- H1 FY25 Comfy Sales: Rs. 59.58 Cr, up 30.54% YoY.
- H1 FY25 Beverages Sales: Rs. 14.34 Cr, up 12.20% YoY.
- Brand Comfy grew 28% in Q2 and 31% in H1.
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 110 | 99 | +11.1% | 84 | +31% |
| Operating profit (EBITDA) | 14 | 7 | +100% | 4 | +250% |
| Operating margin | 12% | 7% | +5 pp | 4.2% | +7.8 pp |
| Profit before tax | 16 | 9 | +77.8% | 6 | +166.7% |
| Net profit (PAT) | 12 | 7 | +71.4% | 5 | +140% |
| EPS (₹) | 4.08 | 2.37 | +72.2% | 1.60 | +155% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q2 FY25 results?
Q2 FY25 Net Sales: Rs. 109.92 Cr, up 10.68% YoY.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.